203 related articles for article (PubMed ID: 36481319)
21. Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.
Russell MC; Garelli AM; Reeves DJ
Ann Pharmacother; 2023 Feb; 57(2):198-206. PubMed ID: 35652704
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC).
Choi DH; Jung HA; Park S; Sun JM; Ahn JS; Ahn MJ; Lee SH
Transl Lung Cancer Res; 2023 Dec; 12(12):2448-2459. PubMed ID: 38205202
[TBL] [Abstract][Full Text] [Related]
23. Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer.
Brazel D; Nagasaka M
Lung Cancer (Auckl); 2021; 12():133-138. PubMed ID: 34880698
[TBL] [Abstract][Full Text] [Related]
24. Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2021 Sep; 27():e934854. PubMed ID: 34565792
[TBL] [Abstract][Full Text] [Related]
25. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
26. EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins.
Remon J; Hendriks LEL; Cardona AF; Besse B
Cancer Treat Rev; 2020 Nov; 90():102105. PubMed ID: 32979839
[TBL] [Abstract][Full Text] [Related]
27. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
28. New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.
Girard N
Curr Treat Options Oncol; 2022 Nov; 23(11):1626-1644. PubMed ID: 36242712
[TBL] [Abstract][Full Text] [Related]
29. Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated
Kim TM; Girard N; Leighl NB; Sabari J; Rahhali N; Schioppa CA; Diels J; Sermon J; Chandler C; Kapetanakis V; Jain R; Li T; Sanden SV
Future Oncol; 2024 Mar; 20(8):447-458. PubMed ID: 37882460
[No Abstract] [Full Text] [Related]
30. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
31. Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Park K; Sabari JK; Haura EB; Shu CA; Spira A; Salgia R; Reckamp KL; Sanborn RE; Govindan R; Bauml JM; Curtin JC; Xie J; Roshak A; Lorenzini P; Millington D; Thayu M; Knoblauch RE; Cho BC
Lung Cancer; 2023 Apr; 178():166-171. PubMed ID: 36868177
[TBL] [Abstract][Full Text] [Related]
32. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
Zhao Y; Wang H; He C
J Cancer Res Clin Oncol; 2021 Dec; 147(12):3653-3664. PubMed ID: 34661758
[TBL] [Abstract][Full Text] [Related]
33. Determination and Confirmation of Recommended Ph2 Dose of Amivantamab in Epidermal Growth Factor Receptor Exon 20 Insertion Non-Small Cell Lung Cancer.
Haddish-Berhane N; Su Y; Russu A; Thayu M; Knoblauch RE; Mehta J; Xie J; Gibbs E; Sun YN; Zhou H
Clin Pharmacol Ther; 2024 Mar; 115(3):468-477. PubMed ID: 37776107
[TBL] [Abstract][Full Text] [Related]
34. Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.
Vijayaraghavan S; Lipfert L; Chevalier K; Bushey BS; Henley B; Lenhart R; Sendecki J; Beqiri M; Millar HJ; Packman K; Lorenzi MV; Laquerre S; Moores SL
Mol Cancer Ther; 2020 Oct; 19(10):2044-2056. PubMed ID: 32747419
[TBL] [Abstract][Full Text] [Related]
35. Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer.
Raoof S; Mulford IJ; Frisco-Cabanos H; Nangia V; Timonina D; Labrot E; Hafeez N; Bilton SJ; Drier Y; Ji F; Greenberg M; Williams A; Kattermann K; Damon L; Sovath S; Rakiec DP; Korn JM; Ruddy DA; Benes CH; Hammerman PS; Piotrowska Z; Sequist LV; Niederst MJ; Barretina J; Engelman JA; Hata AN
Oncogene; 2019 Sep; 38(37):6399-6413. PubMed ID: 31324888
[TBL] [Abstract][Full Text] [Related]
36. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
[TBL] [Abstract][Full Text] [Related]
37. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
38. Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
Wang M; Yang JC; Mitchell PL; Fang J; Camidge DR; Nian W; Chiu CH; Zhou J; Zhao Y; Su WC; Yang TY; Zhu VW; Millward M; Fan Y; Huang WT; Cheng Y; Jiang L; Brungs D; Bazhenova L; Lee CK; Gao B; Xu Y; Hsu WH; Zheng L; Jänne PA
Cancer Discov; 2022 Jul; 12(7):1676-1689. PubMed ID: 35404393
[TBL] [Abstract][Full Text] [Related]
39. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
40. Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy.
Shah V; McNatty A; Simpson L; Ofori H; Raheem F
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]